ArticleFrontiers in cellular and infection microbiology2026
Immunological changes associated with the treatment of pneumonic tularaemia in marmosets.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: Blood samples were collected from marmosets infected with a lethal dose of inhalational tularemia and treated with either oral ciprofloxacin or inhaled ciprofloxacin (Apulmiq®). Immunological responses were assessed longitudinally and compared with immunological changes previously observed in recovering human cases of tularemia. Results: Infected marmosets exhibited increased neutrophil levels, which, together with reduced HLA-DR expression, indicated severe infection. Rising circulating interferon-gamma (IFN γ) levels were followed by classical activation of macrophages as an initial attempt to control bacterial dissemination. Progressive disease was characterised by a marked depletion of neutrophils, excessive IFN γ production, and elevated levels of overactivated macrophages. In animals that responded successfully to treatment, these immunological parameters returned to baseline levels. Recovery was subsequently associated with increased T cell populations, particularly gamma delta T (γδ T) cells, and limited antibody production, suggesting the development of long-term immunity comparable to that observed in humans. Discussion: The observed immunological changes in marmosets closely mirror those reported in human tularemia, supporting the relevance of this model for studying disease progression and recovery. The capacity to monitor these immune parameters demonstrates the utility of the marmoset model in assessing the efficacy of new and novel antibiotic treatments for tularemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.